title: A comparison of budesonide nasal dry powder with fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis.
abstract: There is circumstantial evidence that the incidence of allergic rhinitis is becoming increasingly common. There may also be a need for more potent drugs with minimal local and systemic side effects. This study has compared the efficacy and safety of budesonide delivered as nasal dry powder with fluticasone propionate aqueous nasal spray in the treatment of perennial allergic rhinitis. Ninety-eight patients participated in a randomized, parallel group and partly blinded study. Treatment consisted of budesonide dry powder (Rhinocort Turbuhaler) at once daily doses of 200 micrograms (n = 24) or 400 micrograms (n = 22), fluticasone propionate (200 micrograms) once daily (n = 25), and placebo for budesonide dry powder (n = 27). A six-week treatment period was preceded by a two-week baseline period without treatment. Efficacy was assessed by daily subjective scoring of nasal symptoms. Safety was assessed by rhinoscopy, analysis of urine cortisol, and questioning of adverse events. All active treatments were significantly superior to placebo in controlling nasal symptoms. No significant differences in efficacy were found between the two budesonide regimens and fluticasone propionate. Adverse events were few and minor, and non-significantly distributed between treatments. In conclusion, this study shows that budesonide dry powder administered from Turbuhaler (200 or 400 micrograms) and fluticasone propionate aqueous spray (200 micrograms) administered in once daily doses, are effective and safe treatments of perennial allergic rhinitis. These novel treatments may enhance the current available alternatives in clinical practice.
authors.affiliation: Department of Otorhinolaryngology, University Hospital, Lund, Sweden.
authors.forename: M
authors.initials: M
authors.lastname: Andersson
authors.forename: R
authors.initials: R
authors.lastname: Berglund
authors.forename: L
authors.initials: L
authors.lastname: Greiff
authors.forename: A
authors.initials: A
authors.lastname: Hammarlund
authors.forename: L
authors.initials: L
authors.lastname: Hedbys
authors.forename: I
authors.initials: I
authors.lastname: Malcus
authors.forename: P
authors.initials: P
authors.lastname: Nilsson
authors.forename: P
authors.initials: P
authors.lastname: Olsson
authors.forename: I L
authors.initials: IL
authors.lastname: Sjölin
authors.forename: B
authors.initials: B
authors.lastname: Synnerstad
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000336:Aerosols; D000730:Androstadienes / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D019819:Budesonide; D005260:Female; D000068298:Fluticasone; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011208:Powders; D011282:Pregnenediones / Q000008:administration & dosage*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D000336:Aerosols; D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011208:Powders; D011282:Pregnenediones; D019819:Budesonide; D000068298:Fluticasone